Year Founded
2014
Ownership
Private
Employees
~10
Stage
Phase 1
Modalities
Small molecule

ERX Pharmaceuticals General Information

ERX-1000 completed Phase 1 first-in-human study in healthy obese and non-obese subjects. Company is conducting two concurrent placebo-controlled 28-day studies of 4mg ERX-1000.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Boston, Massachusetts
United States

Drug Pipeline

ERX-1000
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to ERX Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

Boston Children's Hospital

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

ERX Pharmaceuticals Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view ERX Pharmaceuticals's complete valuation and funding history, request access »